Beartrap, I believe you're precisely on the money and in a few years the company will have a major choice to make. Do they wish to be bought out at say twice the current price, I'll presume that to be $50 or more a share, or do they wish to grow into a giant in biotech, perhaps the next Amgen, etc.
In three years time it's doubtful that new trials started this or next year can be near conclusion, but it's very possible that sufficient data has been seen to know that both DCVax-L is truly tumor agnostic, and is being used frequently off label in many cancers, and that DCVax-Direct will be approved as a tumor agnostic product. By that time the investment community will all know about NWBO and double the current price might well be near or at triple digits. By that time it's very possible that we'll have a BP equity partner and that would be the most likely to consider a buyout, but the price tag could easily be $100 billion or more.
Right now there are two keys IMHO, UK approval and acceptance of the EDEN unit for commercial production. I believe it's possible for submissions to go to the other regulators, including the FDA, shortly prior to EDEN acceptance, but the company needs to be certain the acceptance will fall into the timeframe that their applications for approval are being considered.
I know that some investors believe we could proceed with manual production methods alone, perhaps it's possible if we had a contract with CRL to devote a massive number of cleanrooms to such production. I believe that CRL will play a big part in producing DCVax-L in the future, but it will be with the EDEN. I believe the only way we'd go to manual production worldwide would be if acceptance of the EDEN was deemed to be years away. To my way of thinking, UK acceptance by mid-year and others not until early next year is an acceptable scenario, and I believe it's one that will have the EDEN unit doing the commercial production.
Gary
